Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria: * Moderate to severe COPD * Smoking history of greater or equal to 10 pack-years * Diagnosis of stable moderate to severe COPD as defined by the GOLD Guidelines * Postbronchodilator FEV1 from 30% to 79% of predicted values, inclusive * Postbronchodilator FEV1/FVC ratio \< 0.70 Exclusion Criteria: * History or presence of asthma, allergic rhinitis, or exercise-induced bronchospasm * Hospitalization for an acute COPD exacerbation in the 3 months prior to study entry * Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry * Eosinophil count of at least 600 cells/mm3 * Long term oxygen therapy \> 15 hours a day